Nonetheless, though Keytruda will lose patent exclusivity in 2028, its sales are expected to remain strong until then. Merck is also working on different strategies to drive Keytruda's long-term ...

Biologics are antibodies produced by genetically engineered cells and are widely used in therapeutic applications. Examples include pembrolizumab (Keytruda) and atezolizumab (Tecentriq), both employed ...

After a median follow-up of 38.3 months (range, 9.0-66.5), treatment with KEYTRUDA before surgery (neoadjuvant), then continued in combination with standard of care radiotherapy (with or without ...

Key Takeaways Evorpacept and Keytruda combination failed to meet primary endpoints in ASPEN-03 and ASPEN-04 trials for advanced HNSCC. The combination did not improve objective response rates compared ...

Each vial of Keytruda has an official price of €3,566 in Europe ($3,871), an amount subject to confidential discounts. As the drug is administered in doses of 200 or 400 milligrams every three to six ...

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the U.S. on October 1, and expects to hit peak adoption ...

Your Keytruda treatment may last for around 2 years, but certain factors may mean that you’ll receive the drug for a longer or shorter time. If you have questions about what to expect from your ...

The Keytruda market is expected to grow strongly even beyond that point, namely to $45.9 billion by 2032, at a CAGR of 9.20%. Keytruda market projections (Market Research Future) ...

The half-life of Keytruda’s active ingredient, pembrolizumab, is around 22 days. (A drug’s half-life is the amount of time it takes for your body to get rid of half a dose.) ...

This experimental lung cancer drug outperforms blockbuster medicine Keytruda. But there’s a catch In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab ...